INVESTIGADORES
FERNANDEZ Ariel
artículos
Título:
Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy
Autor/es:
FERNÁNDEZ, ARIEL
Revista:
Trends in Cancer
Editorial:
Cell Press
Referencias:
Lugar: Cambridge, Massachusetts; Año: 2017 vol. 3 p. 675 - 677
ISSN:
2405-8033
Resumen:
The immune checkpoint blocker pembrolizumab (Keytruda) has proven successful in treating solid tumors harboring a DNA mismatch repair (MMR) deficiency. We show that it is possible to generate a drug-promoted phenotype mimicking the MMR deficiency in solid tumors, and thereby to engineer a generic hypersusceptibility to Keytruda through drug-induced metabolic stress on DNA synthesis. The potential of such drug?Keytruda combinations as universal treatments for solid tumors deserves clinical evaluation.
